

We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Oncology

Orug class	Platform	Product candidate	Indication (target)	Phase 1	Phase 1/2	Phase 2	Phase 3	BioNTech rights ¹	Collaborator/ Partner
mRNA	FixVac	BNT111	Advanced, R/R melanoma		i	i			
		BNT113	Metastatic/ R/R HPV16+ head and neck cancer					Fully owned ²	
		BNT116	1L metastatic NSCLC Advanced/metastatic NSCLC		I I		1	Í	
	iNeST	BNT122 (autogene cevumeran)	1L advanced melanoma		:				
			Adjuvant colorectal cancer				1	Collaboration	Genentech ³
			Adjuvant pancreatic ductal adenocarcinoma		<u> </u>			l	Generated
			Multiple solid tumors		I	I I ———————————————————————————————————	!		
	RiboMabs	BNT142	Multiple solid tumors (CD3×CLDN6)				i	Fully owned	
	RiboCytokines	BNT152 + BNT153	Multiple solid tumors (IL-7, IL-2)		i	i	i	Fully owned	_
Cell	CAR T cells + CARVac	BNT211	Multiple solid tumors (CLDN6)		I	I I		Fully owned	
therapies	Neoantigen-based T cells	BNT221	Refractory metastatic melanoma		I I I	l l l		Fully owned	
	Next-generation immune checkpoint modulators	BNT311 / GEN1046	aPD(L)1-R/R metastatic NSCLC (PD-L1×4-1BB)						
		(acasunlimab)	Multiple solid tumors (PD-L1×4-1BB)		<u> </u>	l I			
		BNT312 / GEN1042	Multiple solid tumors (CD40×4-1BB) ⁴					Callah anatian	Cammah
		BNT314 / GEN1059	Multiple solid tumors (EpCAM×4-1BB)		-	I I		Collaboration	Genmab
		BNT315 / GEN1055	Multiple solid tumors (OX40)		 	I		 	
		BNT322 / GEN1056	Multiple solid tumors		į		i		
			aPD(L)1-R/R metastatic NSCLC (CTLA-4)				 		
		BNT316 / ONC-392 (gotistobart)	Platinum-resistant ovarian cancer (CTLA-4)] [
			Metastatic castration-resistant prostate cancer		<u>i </u>	I		Collaboration	OncoC4
Protein- based therapeutics			(CTLA-4)		i	i	i i		
			Multiple solid tumors (CTLA-4)			! !			
		BNT327/PM8002 + BNT325/DB-1305	Multiple solid tumors		!	 		Collaboration	Biotheus Duality Biologic
	Targeted cancer antibodies	BNT321	Adjuvant pancreatic ductal adenocarcinoma					Fully owned	
			(sLea)		1	l I			
			Metastatic pancreatic cancer (sLea)		!	l I	!	l 	
	Antibody-drug conjugates		HR+/HER2-low metastatic breast cancer		<u>i </u>	i	<u> </u>		
		BNT323 / DB-1303	(HER2)		i	i	i	! 	
			Multiple solid tumors (HER2)		<u>-</u>	 	!	Collaboration	Duality Biologic
		BNT324 / DB-1311	Multiple solid tumors (B7H3)			: 		: -	, 3
		BNT325 / DB-1305	Multiple solid tumors (TROP2)			 	1		
		BNT326 / YL202	Multiple solid tumors (HER3)				 	Collaboration	MediLink Therapeutics
SMI ⁵	Toll-like receptor binding	BNT411	Multiple solid tumors (TLR7)					Fully owned	



We are advancing a diversified portfolio of product candidates derived from our four drug classes focused on the potential treatment of cancer, infectious diseases and other serious diseases of unmet patient need:

Infectious Diseases

Drug class	Product candidate	Indication	Phase 1	Phase 1/2	Phase 2	Phase 3	Commercial	BioNTech rights	Collaborator/ Partner
mRNA	BNT162b2							 	
	BNT162b2+BNT162b4			1	1	I I	I I	Collaboration	Pfizer
	(T-cell enhancing)	COVID-19		İ		į			Fosun Pharma
	BNT162b5/6/7			!	<u> </u>	! !	 		1 OSull 1 Hailila
	(Stabilized spike antigen)			<u> </u>					
	BNT162b2+BNT1616	COVID-19 – Influenza combination		i	<u> </u>			Collaboration	Pfizer
	BNT161	Influenza						Collaboration ⁷	Pfizer
	BNT163	HSV						Collaboration	University of
				I I	I I	 	l I		Pennsylvania
	BNT164	Tuberculosis ⁸		 	 		 	Fully owned	Funded by Bill & Melinda Gates Foundation
	BNT165	Malaria ⁹			I I] 	Fully owned	
	BNT166	Mpox			İ	İ		Fully owned	Funded by CEPI ¹⁰
	BNT167	Shingles			i			Collaboration	Pfizer
Protein-									
based	BNT331	Bacterial vaginosis		1	!	!	l	Fully owned	
therapeutic	S			i	i	i	i	i I	

¹ For further details about BioNTech's rights see quarterly reports under https://investors.biontech.de/financials-filings/quarterly-reports.

^{2.} FixVac platform is fully owned by BioNTech. The BNT111 and BNT116 Phase 2 trials are jointly conducted with Regeneron as part of a cost-sharing strategic collaboration.

³ A member of the Roche group

⁴ Two Phase 1/2 clinical trials in patients with solid tumors are ongoing in combination with ICI+/- chemotherapy.

⁵ Small molecule immunomodulators

⁶ The COVID-19-Influenza combination is a Phase 3 trial in partnership with Pfizer. Further development is subject to entering into a definitive agreement.

⁷ Out-licensed to Pfizer

⁸ Two Phase 1 clinical trials are ongoing (NCT05537038, Germany and NCT05547464, Republic of South Africa).

⁹ A Phase 1 clinical trial (NCT05581641) and a Phase 1/2 clinical trial (NCT06069544) are ongoing.

¹⁰ Coalition for Epidemic Preparedness Innovations (CEPI)